A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA

a study on Growth Hormone Deficiency

Summary

Eligibility
for people ages 1-18 (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
completion around

Description

Summary

The goal of this study is to genrate evidence on long-term effectiveness and safety of SKYTROFA (lonapegsomatropin) in patients with growth hormone deficiency under routine clinical care

Official Title

A US Multi-center, Prospective, Non-interventional, Long Term, Effectiveness and Safety Study of Patients Treated With SKYTROFA (Lonapegsomatropin)

Details

Patients will be treated according to routine clinical practice, and no additional visits, examinations or tests will be required beyond those performed as part of routine clinical practice except for COAs.

Keywords

Growth Hormone Deficiency, Human Growth Hormone, SKYTROFA

Eligibility

You can join if…

Open to people ages 1-18

  • Patients who are on treatment with SKYTROFA (lonapegsomatropin)
  • Patients being clinically managed in USA
  • Patients with an appropriate written informed consent/assent as applicable for the age of the patient

You CAN'T join if...

  • Patients participating in any interventional clinical study

Locations

  • Ascendis Investigational Site accepting new patients
    San Francisco California 94143 United States
  • Ascendis Investigational Site accepting new patients
    Sacramento California 95821 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Ascendis Pharma Endocrinology Division A/S
ID
NCT05820672
Study Type
Observational [Patient Registry]
Participants
Expecting 900 study participants
Last Updated
Contact us about this trial